Scholarlink

Abstract <p>This study introduces a dual-technique strategy for levofloxacin quantification, combining ultraviolet-visible spectrophotometry and a microfluidic paper-based analytical device (<b>µPAD</b>) to address the need for cost-effective, precise pharmaceutical quality control. Leveraging the reaction between levofloxacin and chlorophenol red, both methods form a colored complex (λ<sub>max</sub> = 574 nm) <i>via</i> an acid-base interaction stabilized by electrostatic and hydrogen bonding. The spectrophotometric method demonstrates high sensitivity (limit of detection (<b>LOD</b>): 2.50 µg/mL, linear range: 5–100 µg/mL) with robust intra-day (relative standard deviation (<b>RSD</b>): 0.946–1.730%) and inter-day precision (RSD: 1.401–2.198%), alongside recovery rates of 91.5–102.6%. In contrast, the µPAD offers portability and rapid analysis (LOD: 10.119 µg/mL, linear range: 100–1000 µg/mL), achieving comparable accuracy (recovery: 90.6–96.1%) with minimal reagent consumption. Both techniques were validated according to the International Council for Harmonization guidelines, exhibiting negligible matrix interference in commercial formulations (Levolen, Levobact, Levofloxacin Vitapure). The spectrophotometric method excels in laboratory settings for precision, while the µPAD enables on-site testing, aligning with green chemistry principles. This dual approach bridges technological gaps, providing versatile tools to ensure accurate dosing, support antimicrobial stewardship, and enhance global pharmaceutical quality control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Innovative Dual-Technique Approach to Levofloxacin Assay: Spectrophotometric Chelation and Microfluidic Paper-Based System for Enhanced Pharmaceutical Quality Control

  • 期刊论文

  • 发表日期：

    2025年9月23日

查看全文
  • Teeba D. Khamis,
  • Raed F. Hassan

摘要

Abstract

This study introduces a dual-technique strategy for levofloxacin quantification, combining ultraviolet-visible spectrophotometry and a microfluidic paper-based analytical device (µPAD) to address the need for cost-effective, precise pharmaceutical quality control. Leveraging the reaction between levofloxacin and chlorophenol red, both methods form a colored complex (λmax = 574 nm) via an acid-base interaction stabilized by electrostatic and hydrogen bonding. The spectrophotometric method demonstrates high sensitivity (limit of detection (LOD): 2.50 µg/mL, linear range: 5–100 µg/mL) with robust intra-day (relative standard deviation (RSD): 0.946–1.730%) and inter-day precision (RSD: 1.401–2.198%), alongside recovery rates of 91.5–102.6%. In contrast, the µPAD offers portability and rapid analysis (LOD: 10.119 µg/mL, linear range: 100–1000 µg/mL), achieving comparable accuracy (recovery: 90.6–96.1%) with minimal reagent consumption. Both techniques were validated according to the International Council for Harmonization guidelines, exhibiting negligible matrix interference in commercial formulations (Levolen, Levobact, Levofloxacin Vitapure). The spectrophotometric method excels in laboratory settings for precision, while the µPAD enables on-site testing, aligning with green chemistry principles. This dual approach bridges technological gaps, providing versatile tools to ensure accurate dosing, support antimicrobial stewardship, and enhance global pharmaceutical quality control.